Currently, there are 435.37M common shares owned by the public and among those 372.77M shares have been available to trade.
The company’s stock has a 5-day price change of 3.19% and 15.85% over the past three months. XP shares are trading 17.22% year to date (YTD), with the 12-month market performance down to -35.58% lower. It has a 12-month low price of $10.82 and touched a high of $22.80 over the same period. XP has an average intraday trading volume of 7.47 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.26%, -3.13%, and -11.98% respectively.
Institutional ownership of XP Inc (NASDAQ: XP) shares accounts for 60.35% of the company’s 435.37M shares outstanding.
It has a market capitalization of $7.50B and a beta (3y monthly) value of 1.13. The stock’s trailing 12-month PE ratio is 9.05, while the earnings-per-share (ttm) stands at $1.53. The company has a PEG of 0.77 and the debt-to-equity ratio at 4.78. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.28% over the week and 4.41% over the month.
Analysts forecast that XP Inc (XP) will achieve an EPS of 2.16 for the current quarter, 2.29 for the next quarter and 10.37 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 2.12 while analysts give the company a high EPS estimate of 2.12. Comparatively, EPS for the current quarter was 1.85 a year ago. Earnings per share for the fiscal year are expected to increase by 10.53%, and 12.95% over the next financial year. EPS should shrink at an annualized rate of 11.80% over the next five years, compared to 23.61% over the past 5-year period.
Looking at the support for the XP, a number of firms have released research notes about the stock. Itau BBA stated their Outperform rating for the stock in a research note on March 18, 2025, with the firm’s price target at $20. UBS coverage for the XP Inc (XP) stock in a research note released on January 24, 2025 offered a Buy rating with a price target of $16. BofA Securities was of a view on December 10, 2024 that the stock is Neutral, while UBS gave the stock Neutral rating on July 11, 2024, issuing a price target of $30- $21. Goldman on their part issued Neutral rating on April 30, 2024.
